These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34950686)

  • 1. Non-classical Vitamin D Actions for Renal Protection.
    Dusso AS; Bauerle KT; Bernal-Mizrachi C
    Front Med (Lausanne); 2021; 8():790513. PubMed ID: 34950686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS; Karagiannis PC; Peyerl FW
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation.
    Dusso AS
    Kidney Int Suppl (2011); 2011 Sep; 1(4):136-141. PubMed ID: 25018912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D in chronic kidney disease.
    Dusso A; González EA; Martin KJ
    Best Pract Res Clin Endocrinol Metab; 2011 Aug; 25(4):647-55. PubMed ID: 21872805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?
    Toussaint ND; Damasiewicz MJ
    Nephrology (Carlton); 2017 Mar; 22 Suppl 2():51-56. PubMed ID: 28429545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
    Andress DL; Coyne DW; Kalantar-Zadeh K; Molitch ME; Zangeneh F; Sprague SM
    Endocr Pract; 2008; 14(1):18-27. PubMed ID: 18238737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future.
    Brandenburg V; Ketteler M
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the biologic role of the vitamin D endocrine system.
    Dusso AS
    Curr Vasc Pharmacol; 2014 Mar; 12(2):272-7. PubMed ID: 23713878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease.
    Dusso AS; Tokumoto M
    Kidney Int; 2011 Apr; 79(7):715-29. PubMed ID: 21270766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency.
    Galassi A; Ciceri P; Porata G; Iatrino R; Boni Brivio G; Fasulo E; Magagnoli L; Stucchi A; Frittoli M; Cara A; Cozzolino M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1333-1349. PubMed ID: 33993809
    [No Abstract]   [Full Text] [Related]  

  • 13. Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation.
    Petkovich M; Melnick J; White J; Tabash S; Strugnell S; Bishop CW
    J Steroid Biochem Mol Biol; 2015 Apr; 148():283-9. PubMed ID: 25446887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy.
    Lau KH; Baylink DJ
    Calcif Tissue Int; 1999 Oct; 65(4):295-306. PubMed ID: 10485982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
    Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
    Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
    Slatopolsky E; Finch JL; Brown AJ; Ritter CS; Mizobuchi M; Plum LA; Clagett-Dame M; Sicinski RR; DeLuca HF
    J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The induction of C/EBPβ contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease.
    Arcidiacono MV; Yang J; Fernandez E; Dusso A
    Nephrol Dial Transplant; 2015 Mar; 30(3):423-33. PubMed ID: 25294851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3).
    Jones G
    Semin Dial; 2007; 20(4):316-24. PubMed ID: 17635821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D supplementation in renal disease: is calcitriol all that is needed?
    Fukagawa M; Komaba H; Hamano T
    Scand J Clin Lab Invest Suppl; 2012; 243():120-3. PubMed ID: 22536772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
    Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
    Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.